Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
Memorial Sloan Kettering Cancer Center
AstraZeneca
National Institutes of Health Clinical Center (CC)
Erasca, Inc.
Revolution Medicines, Inc.
G1 Therapeutics, Inc.
AstraZeneca
Fundación GECP
Chonnam National University Hospital
AstraZeneca